Nashwa El-Gendy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10781341/publications.pdf

Version: 2024-02-01

		759233	839539
19	491	12	18
papers	citations	h-index	g-index

19	19	19	668
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid Dissolution. Journal of Pharmaceutical Sciences, 2009, 98, 2731-2746.	3.3	76
2	Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration. Pharmaceutical Research, 2009, 26, 1752-1763.	3.5	73
3	Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. International Journal of Pharmaceutics, 2009, 369, 136-143.	5.2	65
4	Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. European Journal of Pharmaceutical Sciences, 2011, 44, 522-533.	4.0	35
5	Iodinated NanoClusters as an Inhaled Computed Tomography Contrast Agent for Lung Visualization. Molecular Pharmaceutics, 2010, 7, 1274-1282.	4.6	32
6	Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. International Journal of Pharmaceutics, 2010, 391, 305-312.	5.2	28
7	Agglomerates of Ciprofloxacin Nanoparticles Yield Fine Dry Powder Aerosols. Journal of Pharmaceutical Innovation, 2010, 5, 79-87.	2.4	28
8	Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. Therapeutic Delivery, 2013, 4, 951-980.	2.2	23
9	Development of Budesonide Nanocluster Dry Powder Aerosols: Formulation and Stability. Journal of Pharmaceutical Sciences, 2012, 101, 3445-3455.	3.3	16
10	Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits. Molecular Pharmaceutics, 2015, 12, 2665-2674.	4.6	16
11	NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation. International Journal of Pharmaceutics, 2014, 462, 19-28.	5.2	14
12	NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 341-352.	1.4	14
13	Nanocluster Budesonide Formulations Enhance Drug Delivery through Endotracheal Tubes. Journal of Pharmaceutical Sciences, 2012, 101, 1063-1072.	3.3	12
14	NanoClusters Surface Area Allows Nanoparticle Dissolution with Microparticle Properties. Journal of Pharmaceutical Sciences, 2014, 103, 1787-1798.	3.3	12
15	Antibiotic Activity of Iron-Sequestering Polymers. Biomacromolecules, 2015, 16, 1480-1488.	5.4	12
16	Development of Budesonide Nanocluster Dry Powder Aerosols: Processing. Journal of Pharmaceutical Sciences, 2012, 101, 3425-3433.	3.3	11
17	Development of Budesonide Nanocluster Dry Powder Aerosols: Preformulation. Journal of Pharmaceutical Sciences, 2012, 101, 3434-3444.	3.3	10
18	Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis. Journal of Pharmaceutical Sciences, 2016, 105, 3399-3408.	3.3	9

#	Article	IF	Citations
19	Particle Engineering Technologies for Pulmonary Drug Delivery. , 2011, , 283-312.		5